OneRF for Trigeminal Neuralgia

By Aneeta Prem MBE

OneRF for trigeminal neuralgia is a new medical device now being used and reported on in the United States as a minimally invasive option for facial nerve pain. Clinicians use radiofrequency energy to create a controlled heat lesion. The goal is simple: interrupt pain signals travelling through parts of the trigeminal nerve.

People living with trigeminal neuralgia deserve clear information, not hype. So this post separates what we know from what we still do not know. OneRF for trigeminal neuralgia may matter. Nevertheless, the evidence base remains limited.

What is OneRF?

Clinicians use OneRF in a percutaneous procedure. In practice, a specialist guides a needle through the cheek using imaging to reach the trigeminal nerve. The system then delivers radiofrequency energy that heats and ablates targeted nerve fibres.

Radiofrequency procedures for trigeminal neuralgia are not new. Doctors have used related techniques for years, often when medication no longer controls pain or side effects become difficult. For that reason, OneRF appears to be a new device within an established treatment family, rather than a completely new type of care.

What has been reported publicly so far?

University Hospitals in Cleveland published a statement in December 2025 describing two initial patients treated with the OneRF trigeminal nerve ablation system. The hospital reported pain relief in those cases and noted no complications in that early period.

That report matters because it shows real clinical use. However, early reports cannot answer long-term questions. They cannot show how long relief lasts, and they cannot compare OneRF with other procedures either. In other words, the report offers a starting point, not proof.

What FDA clearance means, and what it does not mean

In August 2025, Practical Neurology reported that the OneRF trigeminal nerve ablation system received FDA clearance for facial pain. Other trade publications also covered the clearance.

FDA clearance allows a company to market a device for an intended use in the United States under the relevant pathway. Even so, clearance does not prove long-term effectiveness. It also does not show that a device outperforms existing options. Only published outcome data and follow-up can answer those questions.

Where OneRF fits among trigeminal neuralgia treatments

In the UK, clinicians usually start trigeminal neuralgia treatment with medication. NICE Clinical Knowledge Summaries state that carbamazepine is the only licensed anticonvulsant with proven efficacy for trigeminal neuralgia. The NHS also explains that carbamazepine is the only medicine licensed for trigeminal neuralgia in the UK, and clinicians typically start at a low dose and increase carefully.

When medication fails or when side effects become too severe, specialist teams may discuss procedures or surgery. These options can include microvascular decompression, radiosurgery, and procedures that deliberately damage parts of the trigeminal nerve to reduce pain signals. NHS information also notes that some procedures cause numbness.

Against that background, OneRF for trigeminal neuralgia sits within the group of destructive percutaneous procedures.

What we already know about radiofrequency procedures

Research on radiofrequency procedures for trigeminal neuralgia often reports strong early pain relief for many patients. Over time, pain can return. In addition, sensory side effects can occur, and clinicians consider these risks part of the trade-off.

University Hospitals’ OneRF explainer describes radiofrequency ablation as a technique used for trigeminal neuralgia and refers to published studies on radiofrequency outcomes as a class. Meanwhile, guidance from the Royal College of Surgeons of England and the Faculty of Dental Surgery explains the usual pathway, from medication to specialist surgery where appropriate.

This context helps people place OneRF in the right category. It supports cautious interest rather than unrealistic expectation.

Known risks and trade-offs

Any destructive trigeminal nerve procedure involves trade-offs.

Possible risks include:

facial numbness
altered sensation that feels unpleasant
eye surface problems if corneal sensation changes, depending on the nerve branch involved
recurrence of pain over time

Risk varies by patient, technique, and the treating team’s experience. So a new device cannot remove risk by default. Evidence has to show the true balance.

The key questions still need answers

People ask fair questions, and they deserve straight answers. At present, public reporting does not answer the following:

How long does pain relief last at 6 months, 12 months, and beyond?
How often does pain return, and what happens when it does?
How common are numbness and dysaesthesia in wider real-world use?
How does OneRF compare with other percutaneous techniques already in use?
Which patients suit destructive procedures, and which should avoid them?

Until published data answers those questions, cautious expectations remain the safest approach.

What this means for patients in the UK

Current public reporting focuses on clinical use in the United States. The sources below do not confirm a UK rollout timeline.

If OneRF reaches the UK, NHS adoption would depend on regulation, clinical evaluation, and commissioning decisions. Even then, clinicians and patients should judge the system on transparent outcomes and independent follow-up.

For now, OneRF for trigeminal neuralgia is worth watching. It remains too early to describe it as a proven advance.

Conclusion

Early reporting can help. However, early reporting can also travel faster than evidence. For that reason, this development sits in a “watch and wait” category: plausible, interesting, but not yet supported by long-term published outcomes or comparative studies.

Trigeminal neuralgia is severe and exhausting. New developments deserve attention, but patients also deserve protection from promises.

As things stand, the OneRF system has FDA clearance, and a US hospital has reported early use in two patients with short-term benefit. Even so, longer-term outcomes, comparative evidence, and real-world complication rates still need published data.

“People living with trigeminal neuralgia deserve careful truth, not early promises. New treatments should attract interest, but evidence must decide their place.”
Aneeta Prem

Sources

University Hospitals statement on initial OneRF cases
University Hospitals OneRF explainer page
Practical Neurology report on FDA clearance
NICE CKS management page for trigeminal neuralgia
NHS trigeminal neuralgia treatment page
Royal College of Surgeons of England TN guideline PDF